• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
UMN Pharma Inc. - Product Pipeline Review - Q4 2010 - Product Image

UMN Pharma Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 27 pages
  • Global Markets Direct

UMN Pharma Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “UMN Pharma Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- UMN Pharma Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of UMN Pharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across READ MORE >



List of Tables
List of Figures
UMN Pharma Inc. Snapshot
UMN Pharma Inc. Overview
Key Information
Key Facts
UMN Pharma Inc. – Research and Development Overview
Key Therapeutic Areas
UMN Pharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
UMN Pharma Inc. – Pipeline Products Glance
UMN Pharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
UMN Pharma Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
UMN Pharma Inc. – Drug Profiles
UMN-0501
Product Description
Mechanism of Action
R&D Progress
UMN-02
Product Description
Mechanism of Action
R&D Progress
UMN-0502
Product Description
Mechanism of Action
R&D Progress
UMN-03
Product Description
Mechanism of Action
R&D Progress
UMN-0503
Product Description
Mechanism of Action
R&D Progress
UMN Pharma Inc. – Pipeline Analysis
UMN Pharma Inc. – Pipeline Products by Therapeutic Class
UMN Pharma Inc. Pipeline Products By Target
UMN Pharma Inc. – Pipeline Products by Molecule Type
UMN Pharma Inc. – Recent Pipeline Updates
UMN Pharma Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 20, 2010: UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial
Oct 05, 2009: UMN Pharma Initiates Phase II Clinical Trial For Avian Influenza A (H5N1) Vaccine Manufactured From Cell-Culture, UMN-0501
Feb 13, 2009: UMN Pharma Presents Favorable Results From Phase I/II Study Of UMN-0501
Jun 18, 2008: UMN Pharma Initiates Phase I/II Trials for Pandemic Influenza Vaccine Manufactured from Cell-culture, UMN-0501
Mar 09, 2006: Crucell And DSM Biologics Announce Per C6 Licensing Agreement With UMN Pharma
Mar 09, 2006: Crucell And DSM Biologics Announce Per C6 Licensing Agreement With UMN Pharma
Mar 09, 2006: Crucell And DSM Biologics Announce Per C6 Licensing Agreement With UMN Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS